Improving Enrollment For Challenging Protocol

A biopharma company developed an ingestible powder composed of non-digestible oligosaccharides specifically for patients with ulcerative colitis (UC), with a goal of positively affecting their gut microbiomes. The study needed to enroll 30 subjects with mild to moderate UC symptoms both domestically and abroad. Elligo was brought on to assist with enrolling 20 subjects in the U.S.
Find out the challenges and solutions in the available case study.
VIEW THE CASE STUDY!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Hydrocarbon Online? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Elligo Health Research
This website uses cookies to ensure you get the best experience on our website. Learn more